Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Siegfried Holding AG (SFZN.SW)
CHF73.70
+0.65 (+0.89%)
CH SIX Healthcare Drug Manufacturers - Specialty & Generic
Address
Untere Bruehlstrasse 4 4800
Zofingen, AG, CH
Zofingen, AG, CH
CEO
Marcel Imwinkelried
Website
siegfried.ch
IPO
1995-04-03
ISIN CH1429326825
Also trades on
London Stock Exchange · 0QQO.L (CHF)
Other OTC · SGFEF (USD)
Swiss Exchange · SFZN.SW (CHF)
Description
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF73.70
+0.65 (+0.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
92.3K
Beta
0.79
Float Shares
39.80M
Free Float %
90.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.24% | +1.61% | +3.94% | -4.55% | +13.61% | +9.50% | -14.17% | +13.37% | +0.25% | +333.95% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
73.70
DCF (Unlevered)
42.90
-41.8%
DCF (Levered)
64.41
-12.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | +1 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.02
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.6% Q4'25: +6.6% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+4.3% Q4'25: -82.2% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.9% Q4'25: -4.9% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+15.8% ★ Q4'25: +17.4% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.6% ★ Q4'25: +25.0% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.8% Q4'25: +0.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.88× Q4'25: 0.82× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 10 EPS Ana. |
Dec 2027 12 Rev. Ana. 10 EPS Ana. |
Dec 2028 10 Rev. Ana. 8 EPS Ana. |
Dec 2029 5 Rev. Ana. 6 EPS Ana. |
Dec 2030 5 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
351.74M
est.
|
399.06M
est: 402.99M (-1.0%)
|
366.27M
est: 363.46M (+0.8%)
|
321.36M
est: 326.05M (-1.4%)
|
318.34M
est: 316.07M (+0.7%)
|
299.77M
est: 361.86M (-17.2%)
|
318.26M
est: 332.76M (-4.4%)
|
288.75M
est: 292.44M (-1.3%)
|
283.04M
est: 279.59M (+1.2%)
|
314.41M
est: 305.23M (+3.0%)
|
328.10M
est: 351.86M (-6.8%)
|
367.80M
est: 401.03M (-8.3%)
|
374.94M
est: 397.88M (-5.8%)
|
315.28M
est: 334.40M (-5.7%)
|
480.57M
est: 466.50M (+3.0%)
|
717.73M
est: 706.00M (+1.7%)
|
750.47M
est: 760.33M (-1.3%)
|
794.30M
est: 797.94M (-0.5%)
|
833.51M
est: 834.32M (-0.1%)
|
845.06M
est: 840.66M (+0.5%)
|
1.10B
est: 1.08B (+2.1%)
|
1.23B
est: 1.25B (-1.7%)
|
1.27B
est: 1.28B (-1.0%)
|
1.29B
est: 1.30B (-0.6%)
|
1.33B
est: 1.35B (-1.4%)
|
1.40B
1.34B – 1.46B
+4.3% YoY
|
1.54B
1.44B – 1.65B
+9.8% YoY
|
1.66B
1.64B – 1.67B
+7.5% YoY
|
1.75B
1.65B – 1.85B
+5.6% YoY
|
1.86B
1.76B – 1.97B
+6.5% YoY
|
| EBITDA |
35.60M
est.
|
101.93M
est: 104.26M (-2.2%)
|
94.31M
est: 82.26M (+14.7%)
|
62.01M
est: 77.78M (-20.3%)
|
84.34M
est: 48.08M (+75.4%)
|
68.57M
est: 90.33M (-24.1%)
|
69.86M
est: 65.57M (+6.6%)
|
147.82M
est: 77.69M (+90.3%)
|
33.84M
est: 41.49M (-18.4%)
|
30.24M
est: 4.37M (+592.5%)
|
37.26M
est: 11.76M (+216.9%)
|
44.87M
est: 45.82M (-2.1%)
|
57.24M
est: 39.49M (+44.9%)
|
51.12M
est: 71.02M (-28.0%)
|
74.37M
est: 78.55M (-5.3%)
|
92.53M
est: 98.81M (-6.4%)
|
110.72M
est: 83.02M (+33.4%)
|
126.63M
est: 108.26M (+17.0%)
|
106.17M
est: 119.07M (-10.8%)
|
132.18M
est: 97.39M (+35.7%)
|
213.54M
est: 104.33M (+104.7%)
|
308.30M
est: 110.90M (+178.0%)
|
241.22M
est: 325.41M (-25.9%)
|
289.49M
est: 328.10M (-11.8%)
|
306.70M
est: 341.05M (-10.1%)
|
355.68M
340.38M – 370.59M
+4.3% YoY
|
390.46M
365.29M – 417.26M
+9.8% YoY
|
419.60M
415.46M – 423.74M
+7.5% YoY
|
442.98M
418.96M – 467.72M
+5.6% YoY
|
471.86M
446.29M – 498.22M
+6.5% YoY
|
| EBIT |
12.86M
est.
|
75.40M
est: 35.86M (+110.3%)
|
62.93M
est: 68.01M (-7.5%)
|
27.03M
est: 56.43M (-52.1%)
|
47.98M
est: 22.49M (+113.3%)
|
32.76M
est: 49.12M (-33.3%)
|
31.37M
est: 37.79M (-17.0%)
|
-82.12M
est: 26.80M (-406.4%)
|
-13.40M
est: -80.98M (+83.5%)
|
-1.25M
est: -30.24M (+95.9%)
|
13.21M
est: 2.65M (+398.3%)
|
17.42M
est: 13.22M (+31.8%)
|
32.83M
est: 17.76M (+84.8%)
|
26.55M
est: 34.29M (-22.6%)
|
40.92M
est: 48.15M (-15.0%)
|
42.53M
est: 66.41M (-36.0%)
|
61.83M
est: 50.01M (+23.6%)
|
77.63M
est: 64.78M (+19.8%)
|
54.41M
est: 79.80M (-31.8%)
|
76.91M
est: 57.25M (+34.3%)
|
130.42M
est: 61.33M (+112.6%)
|
226.35M
est: 65.19M (+247.2%)
|
159.67M
est: 236.34M (-32.4%)
|
204.77M
est: 238.29M (-14.1%)
|
210.33M
est: 247.70M (-15.1%)
|
258.32M
247.21M – 269.16M
+4.3% YoY
|
283.59M
265.30M – 303.05M
+9.8% YoY
|
304.74M
301.74M – 307.75M
+7.5% YoY
|
321.72M
304.28M – 339.70M
+5.6% YoY
|
342.71M
324.13M – 361.85M
+6.5% YoY
|
| Net Income |
7.51M
est.
|
56.20M
est: 35.52M (+58.2%)
|
53.55M
est: 50.69M (+5.6%)
|
16.39M
est: 47.81M (-65.7%)
|
36.53M
est: 15.90M (+129.8%)
|
32.39M
est: 41.79M (-22.5%)
|
49.71M
est: 29.79M (+66.8%)
|
-74.83M
est: 43.68M (-271.3%)
|
-35.26M
est: -71.51M (+50.7%)
|
-16.24M
est: -38.54M (+57.9%)
|
9.60M
est: -18.68M (+151.4%)
|
20.87M
est: 10.94M (+90.7%)
|
53.85M
est: 20.74M (+159.7%)
|
38.56M
est: 45.30M (-14.9%)
|
39.10M
est: 54.59M (-28.4%)
|
27.91M
est: 59.83M (-53.4%)
|
39.73M
est: 29.88M (+33.0%)
|
56.31M
est: 42.71M (+31.8%)
|
53.15M
est: 58.91M (-9.8%)
|
60.87M
est: 53.34M (+14.1%)
|
95.60M
est: 57.14M (+67.3%)
|
156.49M
est: 148.96M (+5.1%)
|
112.77M
est: 1.32B (-91.5%)
|
160.06M
est: 154.10M (+3.9%)
|
168.66M
est: 168.66M (+0.0%)
|
177.66M
151.25M – 188.90M
+5.3% YoY
|
205.01M
173.75M – 221.46M
+15.4% YoY
|
228.24M
209.31M – 260.79M
+11.3% YoY
|
247.44M
230.01M – 265.41M
+8.4% YoY
|
301.51M
280.26M – 323.40M
+21.8% YoY
|
| SGA |
60.30M
est.
|
34.72M
est: 70.23M (-50.6%)
|
28.41M
est: 53.84M (-47.2%)
|
29.56M
est: 49.52M (-40.3%)
|
18.24M
est: 56.61M (-67.8%)
|
18.06M
est: 53.58M (-66.3%)
|
20.78M
est: 48.83M (-57.4%)
|
25.83M
est: 29.18M (-11.5%)
|
31.95M
est: 24.67M (+29.5%)
|
30.72M
est: 34.93M (-12.1%)
|
35.98M
est: 35.39M (+1.7%)
|
49.51M
est: 41.03M (+20.7%)
|
44.15M
est: 49.11M (-10.1%)
|
25.45M
est: 37.15M (-31.5%)
|
36.35M
est: 36.03M (+0.9%)
|
47.52M
est: 55.62M (-14.6%)
|
57.52M
est: 50.87M (+13.1%)
|
58.16M
est: 60.18M (-3.3%)
|
86.86M
est: 62.22M (+39.6%)
|
67.99M
est: 87.17M (-22.0%)
|
70.97M
est: 93.39M (-24.0%)
|
49.20M
est: 99.27M (-50.4%)
|
108.82M
est: 87.42M (+24.5%)
|
98.36M
est: 88.15M (+11.6%)
|
98.78M
est: 91.63M (+7.8%)
|
95.56M
91.45M – 99.56M
+4.3% YoY
|
104.90M
98.14M – 112.10M
+9.8% YoY
|
112.73M
111.62M – 113.84M
+7.5% YoY
|
119.01M
112.56M – 125.66M
+5.6% YoY
|
126.77M
119.90M – 133.85M
+6.5% YoY
|
| EPS |
9.12
est.
|
20.70
est: 18.88 (+9.7%)
|
19.54
est: 19.72 (-0.9%)
|
6.01
est: 4.88 (+23.2%)
|
13.23
est: 11.77 (+12.4%)
|
11.70
est: 12.92 (-9.5%)
|
17.99
est: 11.25 (+60.0%)
|
-27.00
est: 4.01 (-773.6%)
|
-12.79
est: -1.32 (-868.3%)
|
-4.81
est: -1.35 (-255.9%)
|
2.64
est: 2.14 (+23.4%)
|
5.76
est: 5.51 (+4.5%)
|
15.07
est: 9.79 (+54.0%)
|
9.97
est: 11.18 (-10.8%)
|
9.89
est: 9.71 (+1.9%)
|
7.18
est: 0.75 (+857.3%)
|
10.28
est: 1.25 (+723.5%)
|
13.52
est: 1.48 (+816.4%)
|
12.85
est: 1.60 (+701.7%)
|
14.68
est: 1.56 (+841.1%)
|
22.73
est: 2.09 (+986.0%)
|
37.07
est: 3.26 (+1,035.8%)
|
26.61
est: 30.17 (-11.8%)
|
3.71
est: 3.55 (+4.5%)
|
3.85
est: 3.70 (+4.1%)
|
4.02
3.46 – 4.32
+8.7% YoY
|
4.68
3.97 – 5.06
+16.3% YoY
|
5.27
4.78 – 5.96
+12.8% YoY
|
5.65
5.26 – 6.07
+7.2% YoY
|
6.89
6.40 – 7.39
+21.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
78.87M
OE per share TTM
1.81
Owner's Yield
2.20%
Maintenance CapEx ratio
78.19%
Maint CapEx / Avg PPE
67.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 103 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.51% | 1.61M | 0.31% |
| 2 | iShares STOXX Europe Small 200 UCITS ETF (DE) EXSE.DE | 0.47% | 3.24M | 0.20% |
| 3 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.40% | 4.55M | 0.40% |
| 4 | Avantis International Small Cap Value ETF AVDV | 0.31% | 58.70M | 0.36% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.26% | 875.3K | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.26% | 875.3K | 0.23% |
| 7 | Invesco STOXX Europe 600 Optimised Health Care UCITS ETF SC0T.DE | 0.23% | 31.8K | 0.20% |
| 8 | iShares MSCI Europe Small-Cap ETF IEUS | 0.23% | 394.7K | 0.41% |
| 9 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.22% | 7.42M | 0.30% |
| 10 | iShares STOXX Europe 600 Health Care UCITS ETF (DE) EXV4.DE | 0.19% | 1.52M | 0.46% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
54.0K
Shares Outstanding
43.81M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marcel Imwinkelried | Chief Executive Officer & Chief Operating Officer Drug Products ad interim | 2M | male |
| Enno Schweinberger | Head Global Quality Management DS - Zofingen | — | male |
| Florent Trouillet | Head Corporate Quality Systems - Global Quality Systems | — | — |
| John Jones | Head of Operations - Malta | — | — |
| Luca Dalla Torre | Chief Legal & Sustainability Officer | — | — |
| Olesia Silanteva | Chief Human Resources Officer | — | female |
| Peter Stierli | Head of Corporate Communications | — | male |
| Reto Suter | Chief Financial Officer | — | — |
| Beatrice Harder | Head Regulatory Affairs - Site Zofingen | — | — |
| Stefan Randl | Interim Chief Operating Officer Drug Substances & Chief Scientific Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SFZN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
